Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.52
-3.8%
$1.85
$1.12
$4.20
$113M0.92200,395 shs83,516 shs
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
$11.17
$11.15
$3.46
$19.00
$299.85M1.31212,171 shs330 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.45
-0.7%
$1.50
$0.82
$3.10
$115.43M-0.23864,151 shs357,101 shs
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$4.04
+8.0%
$2.82
$1.11
$5.18
$503.02M2.332.39 million shs4.71 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-3.80%-14.12%-17.84%-32.44%+7.80%
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
0.00%0.00%0.00%0.00%0.00%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-0.68%-3.97%-3.33%-51.67%+34.26%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
+8.02%-4.04%+31.60%+140.48%-27.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.0854 of 5 stars
3.33.00.00.01.50.01.3
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
2.2169 of 5 stars
3.53.00.00.00.00.01.9
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
3.7426 of 5 stars
4.41.00.00.03.05.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50327.63% Upside
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
0.00
N/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00934.48% Upside
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
2.75
Moderate Buy$9.25128.96% Upside

Current Analyst Ratings Breakdown

Latest OYST, PRME, IKT, and PLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
5/27/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00 ➝ $1.50
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.00
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/19/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
$24.54M12.22N/AN/A$3.80 per share2.94
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$59.76M1.93$0.08 per share17.80$0.47 per share3.09
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$3.85M141.28N/AN/A$1.37 per share2.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.04N/A4.68N/A-21.03%-30.89%-11.74%N/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/A

Latest OYST, PRME, IKT, and PLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A-$0.05N/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$1.4535.79%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
8.49
3.35
3.11
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
N/A
6.50
6.50

Institutional Ownership

CompanyInstitutional Ownership
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
96.70%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
70.37%

Insider Ownership

CompanyInsider Ownership
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.30%
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
17.90%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
22.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.34 million66.18 millionNot Optionable
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
30326.84 million22.04 millionNot Optionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.61 million69.00 millionOptionable
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
234134.50 million100.38 millionOptionable

Recent News About These Companies

Prime Medicine Halts Sales Agreement Prospectus
Prime Medicine (NYSE:PRME) Shares Gap Down - Here's Why
Prime Medicine stock falls after pricing public offering
Prime Medicine (NYSE:PRME) Trading Up 6.9% - Here's Why
Prime Medicine Announces Pricing of Public Offering
Prime Medicine (NYSE:PRME) Trading Down 8.9% - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$1.52 -0.06 (-3.80%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.52 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Oyster Point Pharma stock logo

Oyster Point Pharma NASDAQ:OYST

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.45 -0.01 (-0.68%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.03%)
As of 08/1/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Prime Medicine stock logo

Prime Medicine NYSE:PRME

$4.04 +0.30 (+8.02%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.34 +0.30 (+7.33%)
As of 08/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.